insights_auto
Why is HROW down 3.80%?
Dive Deeperchevron_right
HROW:NASDAQ
Harrow Inc
$29.36
arrow_downward
-3.80%(-1.16) 1D
$29.61
arrow_upward
+0.85% (+0.25)bedtimeAfter hours
Closed: Oct 9, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HROW...
Open
$30.73
High
$30.90
Low
$27.00
Mkt. cap
1.10B
Avg. vol.
550.16K
Volume
1.35M
52-wk high
$54.85
52-wk low
$27.00
EPS
-$1.00
Beta
0.19
Shares outstanding
37.49M
No. of employees
373
Open
$30.73
High
$30.90
Low
$27.00
Mkt. cap
1.10B
Avg. vol.
550.16K
Volume
1.35M
52-wk high
$54.85
52-wk low
$27.00
EPS
-$1.00
Beta
0.19
Shares outstanding
37.49M
No. of employees
373
News stories
From web sources and news partners
https://www.dars.gov.et/
·
2 months ago
HROW Q1 2026 Earnings: EPS Misses Estimates by a Wide Margin as Shares Climb 3.18% - Revenue Guidance Range
Profile
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing.
In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its chief innovation officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary. Wikipedia
About Harrow Inc
CEOMark L. Baum Esq.
Employees373
Founded2012
HeadquartersNashville, Tennessee, United States
SectorPharmaceutical industry
Websiteharrow.com